Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



 
ABG WTT-Ceribell Limited
 
Signature:/s/ Kevin Reilly
Name/Title:Kevin Reilly, Director
Date:05/02/2025
 
ABG V-Ceribell Limited
 
Signature:/s/ Kevin Reilly
Name/Title:Kevin Reilly, Director
Date:05/02/2025
 
Ally Bridge Group Global Life Science Capital Partners V, L.P.
 
Signature:By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general p
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG Global Life Science Capital Partners V GP, L.P.
 
Signature:By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG Global Life Science Capital Partners V GP Limited
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
 
Signature:By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its gener
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG-WTT Global Life Science Capital Partners GP, L.P.
 
Signature:By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG-WTT Global Life Science Capital Partners GP Limited
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG Management Ltd.
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
Ally Bridge Group (PE) LLC
 
Signature:By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
Fan Yu
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu
Date:05/02/2025
Exhibit Information

[Exhibit A - Joint Filing Agreement]

 

 

 

Exhibit A

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G dated May 2, 2025 relating to the Common Stock, $0.001 par value per share, of Ceribell, Inc. shall be filed on behalf of the undersigned.

 

ABG WTT-CERIBELL LIMITED

 

By: /s/ Kevin Reilly

  Name: Kevin Reilly
  Title:   Director

 

 

 

ABG V-CERIBELL LIMITED

 

By: /s/ Kevin Reilly

  Name: Kevin Reilly
  Title:   Director

 

 

 

ALLY BRIDGE GROUP GLOBAL LIFE SCIENCE CAPITAL PARTNERS V, L.P

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ABG GLOBAL LIFE SCIENCE CAPITAL PARTNERS V GP, L.P.

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ABG GLOBAL LIFE SCIENCE CAPITAL PARTNERS V GP LIMITED

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ALLY BRIDGE GROUP-WTT GLOBAL LIFE SCIENCE CAPITAL PARTNERS, L.P.

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ABG-WTT GLOBAL LIFE SCIENCE CAPITAL PARTNERS GP, L.P.

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ABG-WTT GLOBAL LIFE SCIENCE CAPITAL PARTNERS GP LIMITED

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ABG MANAGEMENT LTD.

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

ALLY BRIDGE GROUP (PE) LLC

 

By: /s/ Fan Yu

  Name: Fan Yu
  Title:   Director

 

 

 

FAN YU

 

By: /s/ Fan Yu